Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 266704
License Grant
Licensor grants to Licensee a royalty bearing license in the Territory in the Field, with the right to grant sublicenses, under the Compound Patent Rights, which Compound Patent Rights license shall be exclusive and the Licensor Know-How, which Licensor Know-How license shall be non-exclusive, to Develop, Manufacture, have Manufactured, use, import, export and Commercialize the Licensed Compounds and the Licensed Products in the Field in the Territory during the Term.
License Property
The patents include Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose) polymerase(P ARP) inhibitors; Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors; Pharmaceutically acceptable salts of 2-{ 4-[(3S)-piperidin-3-yl]phenyl} -2-indazole-7-carboxamide; and, Pyridazinone derivatives as PARP inhibitors.
Licensed Compounds shall mean those certain Licensor compounds currently known as M_-4827 with the following chemical name 2 [4 (3S) 3 PIPERIDINYLPHENYL] 2H INDAZOLE 7 CARBOXAMIDE and M_-2512 with the following chemical name 6 (3 [(4 CYCLOPENTYL 3 OXYPIPERAZIN 1 XL)CARBONYL] 4 FLUOROBENZYL] 4,5 DIMETHYLPYRIDAZIN 3(21-l) ONE], and with respect to both, shall include any pharmaceutically acceptable salt, polymorph, crystal form, prodrug or solvate thereof that but for the license granted, would infringe the Compound Patent Rights.
M_-4827, also known as Niraparib, is an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor in cancer patients as a monotherapy.
M_-2512 is the backup PARP inhibitor compound.
Field of Use
This agreement includes the development of niraparib for the treatment of tumor. Niraparib is aprescribed PARP inhibitor to treat cancer.
IPSCIO Record ID: 369278
License Grant
Licensor hereby grants to Licensee a royalty-bearing, non-transferable license, with the right to grant sublicenses as provided in Agreement, under the Licensor Technology and Licensor Trademarks, which license shall be non-exclusive with respect to the Merck Know-How and exclusive (even as to Licensor, except to the extent necessary for Licensor to perform its obligations under this Agreement with respect to any Licensor Technology (other than the Merck Know-How) and the Licensor Trademarks, to Exploit the Compounds and Products in the Licensee Field in the Licensee Territory. The foregoing license grant by Licensor does not include any grant of rights under the Licensor Technology or Licensor Trademarks to Exploit any active pharmaceutical compound that is not a Compound, other than, to the extent applicable, any API(s) Controlled by Licensor (if any) that are included in a Product that is deemed to be a Single Agent Product pursuant to this Agreement.
License Property
Product means any pharmaceutical product, including all forms, presentations, strengths, doses and formulations (including any method of delivery), containing a Compound alone or in combination with other APIs. For the sake of clarity, all forms, presentations, doses and formulations of a pharmaceutical product containing a Compound shall be considered the same Product for purposes of this Agreement, so long as each form, presentation, dose and formulation contains the same Compound and same other APIs (and no other Compounds or other APIs).
Compound means (a) the Initial Compound; (b) the compound licensed to Licensor under the Merck License Agreement and known as MK-2512; or (c) with respect to both (a) and (b), any pharmaceutically acceptable salt, polymorph, crystal form, prodrug or solvate thereof.
Licensor Patents means all Patents Controlled by Licensor during the Term that are necessary or useful to Exploit the Compounds or Products in the Licensee Field in the Licensee Territory. Licensor Patents include, as of the Effective Date, those Patents set forth in Exhibit 1.117, the Merck Patents and AstraZeneca Patents.
US #8071623 – Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
US #8436185 – Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
US #8188084 – Pyridinone and pyridazinone derivatives as inhibitors of poly (ADP-ribose) polymerase (PARP)
Trademark means any word, name, symbol, colour, designation, slogan, catch phrase or device or any combination thereof used or intended to be used in commerce and indicating the source for a product or service, including any domain name, trademark, trade dress, brand mark, trade name, brand name, logo or business symbol, any registrations of any of the foregoing or any pending applications therefor.
Field of Use
The collaboration and license agreement focused on the development and commercialization of niraparib specifically for the treatment of prostate cancer. Niraparib is an oral, once daily, potent, and highly selective PARP inhibitor that is currently being evaluated in Phase 3 clinical trials for ovarian and breast cancer.
IPSCIO Record ID: 321858
License Grant
This amendment increases the royalties for dostarlimab and adds terms for Zejula.
License Property
Dostarlimab is an anti-PD-1 antagonist antibody.
Zejula TM is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor.
Field of Use
Dostarlimab is under development for multiple oncological disorders, including endometrial cancer, non-small cell lung cancer, ovarian cancer, colorectal cancer and mismatch repair deficient solid tumors.
Zejula, which has received US approval for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
IPSCIO Record ID: 348663
License Grant
By the Amendment, both parties agree to permit Licensee to conduct development and commercialization of Zejula.
In addition, under the Amendment, Licensor granted increased royalties upon sales of JEMPERLI (dostarlimab).
Additionally, Licensee has agreed to certain diligence commitments with respect to the future development of JEMPERLI, and the parties have agreed to review such commitments under regular joint review committee meetings going forward.
License Property
Zejula is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, which has received U.S. approval.
JEMPERLI (dostarlimab) is an anti-PD-1 antagonist antibody.
Field of Use
Zejula is for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, and is under development for additional cancer indications.
JEMPERLI (dostarlimab) is under development for multiple oncological disorders.
IPSCIO Record ID: 239024
License Grant
The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.
License Property
The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.
Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.
Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.
Field of Use
Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
